MEDIFAST INC
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Nicholas M. Johnson
- Full Time Employees
- 380
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 1501 S. Clinton Street Baltimore MD United States 21224
- IPO Date
- Dec 30, 1993
- CIK
- 0000910329
- Website
- medifastinc.com
- Similar Companies
- Business
- Medifast, Inc. Medifast, Inc. (NYSE: MED) operates as a health and wellness company that develops, manufactures, and sells clinically proven nutrition products and coach-guided lifestyle programs primarily through its OPTAVIA brand; core offerings include portion-controlled meal replacements such as bars, shakes, soups, puddings, oatmeal, pancakes, smoothies, and soft bakes, alongside the 5 & 1 Plan featuring Lean & Green meals, the Habits of Health Transformational System, and specialized lines like OPTAVIA ACTIVE for muscle health with Essential Amino Acid Blends and whey protein, and OPTAVIA ASCEND high-protein mini meals and nutrient packs tailored for GLP-1 medication users and weight maintenance. Products reach customers via a network of independent OPTAVIA Coaches using direct sales, e-commerce, and community support, targeting consumers seeking weight management, metabolic health, and lifelong healthy habits in the United States weight management market. Founded in 1980 and headquartered in Baltimore, Maryland, the company conducts operations mainly in the U.S. with over 40 years of experience, subsidiaries including Optavia (formerly Take Shape for Life), Jason Pharmaceuticals, and recent innovations backed by a Scientific Advisory Board. Recent developments encompass the 2024 launch of OPTAVIA ASCEND to address gaps in GLP-1 support and muscle preservation, an ongoing collaboration with LifeMD providing coach clients access to clinicians and GLP-1 medications including joint marketing pilots, a planned 2025 program with new OPTAVIA ASCEND products and a clinical study on integrated nutrition-lifestyle outcomes, and optimized marketing spend reductions to $20-25 million for 2024 while enhancing coach productivity amid revenue adjustments.
Company News
Why Is Weight Loss Different During Menopause? Common Myths Debunked
Medifast to Announce Financial Results for the Third Quarter Ended September 30, 2026
Best Momentum Stocks to Buy for October 14th
New Strong Buy Stocks for October 14th
5 Questions People Ask When Every Weight Loss Approach Has Failed
What Actually Keeps Weight Off After a Weight Loss Program
Can Medifast's Better Client Retention Support Revenue Stabilization?
Why Do You Keep Gaining Weight Back After Losing It
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?
Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update
Medifast® Announces the Launch of the Medifast Metabolic Health Institute™
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
All You Need to Know About Medifast (MED) Rating Upgrade to Buy
Great Lakes Advisors LLC Invests $548,000 in Medifast Inc $MED
Can Medifast's New Compensation Plan Accelerate Coach Growth?
Can Medifast's Coach Productivity Gains Help Revive Revenue Growth?
Is MED Worth Buying as Low Valuation Meets a High-Risk Turnaround?